Lastacaft 2.5 mg/1mL

Lastacaft Solution / drops is a product of Allergan

Group: Approved Histamine H1 Antagonists

Name: Lastacaft

Dosage: Solution / drops

Strength: 2.5 mg/1mL

Route: Ophthalmic

Pharmaceutical company : Allergan

You can also find other alternative products such as : Lastacaft (2.5 mg/1mL) from Rebel Distributors Lastacaft (2.5 mg/1mL) from Vistakon Pharmaceuticals, LLC Lastacaft (2.5 mg/1mL) from Allergan Lastacaft (2.5 mg/1mL) from Vistakon Pharmaceuticals, LLC

Indication: For the prevention of itching associated with allergic conjunctivitis.

Category:

  • Decongestants and Antiallergics
  • Histamine Agents
  • Histamine Antagonists
  • Histamine H1 Antagonists
  • Neurotransmitter Agents
  • Ophthalmologicals
  • Potential QTc-Prolonging Agents
  • QTc Prolonging Agents
  • Sensory Organs
  • Food Interactions; Not Available

    Alcaftadine Definition:
    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

    More Lastacaft 2.5 mg/1mL

    LASTACAFT Rx

    Therapeutic indications Ocular allergy/inflammation


    Nursing mothers..Indications for LASTACAFT: Prevention of ocular itching associated with allergic conjunctivitis..


    LASTACAFT Rx

    Therapeutic indications Ocular allergy/inflammation


    Nursing mothers.. Pharmacological Class: H1 histamine receptor antagonist..


    Lastacaft Drops

    Therapeutic indications This medication is used to prevent itching of the eyes due to allergies

    If you notice other effects not listed above, contact your doctor or pharmacist.. You may report side effects to Health Canada at 1-866-234-2345.. You may report side effects to FDA at 1-800-FDA-1088 or at www..
    If you develop an eye infection or eye injury, or require eye surgery, ask your doctor if you should continue to use your current bottle of alcaftadine eye drops or start a new bottle.. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist..It is unknown if this drug passes into breast milk..


    Effects of Lastacaft 2.5 mg/1mL by reaction with another drug or drugs

  • Methotrexate may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alcaftadine.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Pentamidine.
  • Tobramycin may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • Alcaftadine may decrease the excretion rate of Warfarin which could result in a higher serum level.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Sulfisoxazole.
  • Oxaprozin may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • Verapamil may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • The risk or severity of QTc prolongation can be increased when Sertraline is combined with Alcaftadine.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Pheniramine.
  • Tenoxicam may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • Methyldopa may decrease the excretion rate of Alcaftadine which could result in a higher serum level.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Chlorpromazine.
  • The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Alcaftadine.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Moxifloxacin.
  • Eplerenone may increase the excretion rate of Alcaftadine which could result in a lower serum level and potentially a reduction in efficacy.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Flupentixol.
  • The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Alcaftadine.
  • The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Alcaftadine.
  • The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Quinine.